Literature DB >> 30037813

MALDI Mass Spectrometry Imaging Reveals Heterogeneous Distribution of Tenofovir and Tenofovir Diphosphate in Colorectal Tissue of Subjects Receiving a Tenofovir-Containing Enema.

Herana Kamal Seneviratne1, Craig W Hendrix1, Edward J Fuchs1, Namandjé N Bumpus2.   

Abstract

Efforts to prevent human immunodeficiency virus (HIV) infection via pre-exposure prophylaxis (PrEP) include the development of anti-HIV drugs as microbicides for topical application to the mucosal sites of infection; however, although understanding the distribution profiles of these drugs in target mucosal tissues is of critical importance to guiding their optimization, data in this regard are largely lacking. With this in mind, we developed a matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) approach to visualize tenofovir (TFV), an HIV nucleotide analog reverse-transcriptase inhibitor under investigation for use as a topical microbicide, and its active metabolite TFV-diphosphate (TFV-DP) in colorectal biopsies obtained from healthy volunteers who received TFV-containing enemas. Application of MALDI MSI resulted in sufficient spatial resolution to visualize both TFV and TFV-DP and revealed heterogeneity in the distribution profiles of both analytes, including the presence of regions in which TFV and TFV-DP were undetectable, in colorectal tissue at two different time points and concentrations. Cell-specific staining for CD4 T and CD11c dendritic cells, which are important to the establishment of HIV infection, demonstrated that the TFV and TFV-DP distributions were independent of these cell types. MALDI MSI of endogenous lipids demonstrated that the heterogeneity observed for TFV and TFV-DP was not a function of tissue composition or processing. These data provide unique insight into the spatial distribution of TFV and TFV-DP in human colorectal tissue. In addition, this work establishes an approach that can be leveraged to directly detect and visualize these clinically important analytes more broadly in tissue.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30037813      PMCID: PMC6123665          DOI: 10.1124/jpet.118.250357

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

Review 1.  Mass spectrometry imaging for drugs and metabolites.

Authors:  Tyler Greer; Robert Sturm; Lingjun Li
Journal:  J Proteomics       Date:  2011-04-13       Impact factor: 4.044

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

3.  Virtual computational chemistry laboratory--design and description.

Authors:  Igor V Tetko; Johann Gasteiger; Roberto Todeschini; Andrea Mauri; David Livingstone; Peter Ertl; Vladimir A Palyulin; Eugene V Radchenko; Nikolay S Zefirov; Alexander S Makarenko; Vsevolod Yu Tanchuk; Volodymyr V Prokopenko
Journal:  J Comput Aided Mol Des       Date:  2005-06       Impact factor: 3.686

4.  HIV-negative male couples' attitudes about pre-exposure prophylaxis (PrEP) and using PrEP with a sexual agreement.

Authors:  Jason W Mitchell; Ji-Young Lee; Cory Woodyatt; José Bauermeister; Patrick Sullivan; Rob Stephenson
Journal:  AIDS Care       Date:  2016-04-07

5.  Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.

Authors:  M D Miller; N A Margot; K Hertogs; B Larder; V Miller
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2001 Apr-Jul       Impact factor: 1.381

6.  Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA.

Authors:  B L Robbins; R V Srinivas; C Kim; N Bischofberger; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6).

Authors:  Kelly Bleasby; Laura A Hall; Jennifer L Perry; Harvey W Mohrenweiser; John B Pritchard
Journal:  J Pharmacol Exp Ther       Date:  2005-05-24       Impact factor: 4.030

8.  Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).

Authors:  Craig W Hendrix; Adriana Andrade; Namandjé N Bumpus; Angela D Kashuba; Mark A Marzinke; Ayana Moore; Peter L Anderson; Lane R Bushman; Edward J Fuchs; Ilene Wiggins; Christine Radebaugh; Heather A Prince; Rahul P Bakshi; Ruili Wang; Paul Richardson; Eugenie Shieh; Laura McKinstry; Xin Li; Deborah Donnell; Vanessa Elharrar; Kenneth H Mayer; Kristine B Patterson
Journal:  AIDS Res Hum Retroviruses       Date:  2015-10-15       Impact factor: 2.205

9.  PrEP awareness and perceived barriers among single young men who have sex with men.

Authors:  Jose A Bauermeister; Steven Meanley; Emily Pingel; Jorge H Soler; Gary W Harper
Journal:  Curr HIV Res       Date:  2013-10       Impact factor: 1.581

Review 10.  Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.

Authors:  Brian P Kearney; John F Flaherty; Jaymin Shah
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more
  3 in total

Review 1.  Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities.

Authors:  Donglu Zhang; Cornelis E C A Hop; Gabriela Patilea-Vrana; Gautham Gampa; Herana Kamal Seneviratne; Jashvant D Unadkat; Jane R Kenny; Karthik Nagapudi; Li Di; Lian Zhou; Mark Zak; Matthew R Wright; Namandjé N Bumpus; Richard Zang; Xingrong Liu; Yurong Lai; S Cyrus Khojasteh
Journal:  Drug Metab Dispos       Date:  2019-07-02       Impact factor: 3.922

2.  Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.

Authors:  Manjula Gunawardana; Mariana Remedios-Chan; Debbie Sanchez; Simon Webster; Amalia E Castonguay; Paul Webster; Christopher Buser; John A Moss; MyMy Trinh; Martin Beliveau; Craig W Hendrix; Mark A Marzinke; Michael Tuck; Richard M Caprioli; Michelle L Reyzer; Joseph Kuo; Philippe A Gallay; Marc M Baum
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

3.  Spatial Distribution Profiles of Emtricitabine, Tenofovir, Efavirenz, and Rilpivirine in Murine Tissues Following In Vivo Dosing Correlate with Their Safety Profiles in Humans.

Authors:  Herana Kamal Seneviratne; Allyson N Hamlin; Carley J S Heck; Namandjé N Bumpus
Journal:  ACS Pharmacol Transl Sci       Date:  2020-04-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.